| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4028958 | Ophthalmology | 2007 | 12 Pages |
Abstract
Patients with minimally classic or occult with no classic neovascular AMD treated with ranibizumab demonstrated improvement that was consistent for visual acuity, FA, and OCT outcomes and superior to that in sham-treated patients.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Peter K. MD, Barbara A. MD, Howard PhD, Nisha R. MD, MS, MARINA Study Group MARINA Study Group,